Global Pipeline Review for Caspase 3 - H1 2020 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 3, 2020--
The “Caspase 3 - Pipeline Review, H1 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.
This pipeline outlays comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 126.96.36.199) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Reasons to buy
Key Topics Covered:
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/noaxgs
View source version on businesswire.com:https://www.businesswire.com/news/home/20200203005578/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2020.
PUB: 02/03/2020 10:58 AM/DISC: 02/03/2020 10:58 AM